Non-profits are uniquely positioned to drive innovative, low-cost approaches to new treatment options. In this talk co-hosted by the Therapeutic Development and AI/LLM Learning Communities, Dr. Laura Kleiman, founder of... read more →
Many non-profit organizations fund biomedical research that ultimately aims to improve human health. This session provided an overview of the translational science pipeline and explored ways in which non-profit funders... read more →
This Therapeutic Development Learning Community session explored balancing the drive for open science with the need to protect key aspects of a scientist's work if the goal is one day... read more →
As non-profits, we want to make sure any investments we make in potential new therapeutics are as impactful as possible. In this session, we explored how we can complement what... read more →
In this community call, the new co-chair team (Mary O’Reilly, Maaike Everts, Raeka Aiyar) facilitated an open discussion to reboot the Therapeutic Development (formerly known as Drugs and Other Therapy... read more →
We held a one hour session where Mark Roithmayr, CEO Alzheimer’s Drug Discovery Foundation (a pure Venture Philanthropy nonprofit), interviewed John Walter, CEO Food Allergy Science Initiative, who has helped... read more →
Building on past presentations where we spotlighted the individual efforts of the Leukemia & Lymphoma Society, Foundation Fighting Blindness, and JDRF, in another of our Venture Philanthropy series we heard... read more →
The Flinn Foundation launched the bioscience Entrepreneurship Program in 2014 to foster entrepreneurship and help bioscience founders/CEOs develop their early-stage companies into successful and sustainable businesses bringing new therapies, medical... read more →
In November 2016, HRA sponsored a workshop at the FDA entitled “Gene Editing: FDA-Regulated Technologies and Applications.” The keynote speaker was Jennifer Doudna and her talk was titled “CRISPR-Cas Genome... read more →
Venture philanthropy does not come without its fair share of controversy. It remains a challenge for nonprofits, philanthropists, patients, start-ups and the general public to determine how – and if... read more →